ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

Session ID: 2025-07-04:dfc7b8c17c83ea48a7aa25 Player Element ID: vjs_video_3 ...

BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd.

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results Published on July 2, 2025 at 2:46 am by Sheryar Siddiq in News ...

ASCO’s own take on the data, delivered by official expert Merry Jennifer Markham, is that more research is needed, but the trial “is indeed promising for patients with advanced ovarian cancer.” ...

ASCO 2025 – NSCLC The latest news from ASCO 2025 focusing on NSCLC including abstracts, features, and helpful conference information. In NSCLC, Complete Blood Count a Promising Prognostic Biomarker A ...

Are you currently a college student entering your junior year or higher or recent graduate, or do you know someone who is? Get ready to immerse yourself in the adventure of our dynamic internship ...

It is still an unmet need. MATTERHORN is a big step, but there's a lot more work to do. We want to cure more patients. There are a lot of new targets, new drugs, and some of the highlights we saw at ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) that target estrogen receptors through new mechanisms, highlighting modest ...

SPARGO, Inc. is the only official registration and housing provider for ASCO Meetings and Symposia. Individuals unaffiliated with ASCO or SPARGO, Inc. may entice prospective attendees into registering ...

ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...